Literature DB >> 18565859

Rhythm control versus rate control for atrial fibrillation and heart failure.

Denis Roy1, Mario Talajic, Stanley Nattel, D George Wyse, Paul Dorian, Kerry L Lee, Martial G Bourassa, J Malcolm O Arnold, Alfred E Buxton, A John Camm, Stuart J Connolly, Marc Dubuc, Anique Ducharme, Peter G Guerra, Stefan H Hohnloser, Jean Lambert, Jean-Yves Le Heuzey, Gilles O'Hara, Ole Dyg Pedersen, Jean-Lucien Rouleau, Bramah N Singh, Lynne Warner Stevenson, William G Stevenson, Bernard Thibault, Albert L Waldo.   

Abstract

BACKGROUND: It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied.
METHODS: We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation. The primary outcome was the time to death from cardiovascular causes.
RESULTS: A total of 1376 patients were enrolled (682 in the rhythm-control group and 694 in the rate-control group) and were followed for a mean of 37 months. Of these patients, 182 (27%) in the rhythm-control group died from cardiovascular causes, as compared with 175 (25%) in the rate-control group (hazard ratio in the rhythm-control group, 1.06; 95% confidence interval, 0.86 to 1.30; P=0.59 by the log-rank test). Secondary outcomes were similar in the two groups, including death from any cause (32% in the rhythm-control group and 33% in the rate-control group), stroke (3% and 4%, respectively), worsening heart failure (28% and 31%), and the composite of death from cardiovascular causes, stroke, or worsening heart failure (43% and 46%). There were also no significant differences favoring either strategy in any predefined subgroup.
CONCLUSIONS: In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy. (ClinicalTrials.gov number, NCT00597077.) 2008 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565859     DOI: 10.1056/NEJMoa0708789

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  341 in total

1.  MEDEX South Carolina: a progress report.

Authors:  K J Buhmeyer; A R Hutson
Journal:  J S C Med Assoc       Date:  1975-11

2.  [Extrabronchial effects of Bronchodilat in patients with asthma and chronic asthmatic bronchitis].

Authors:  J Rozniecki; W Grabski
Journal:  Gruzlica       Date:  1975-11

3.  Augmented single-unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation.

Authors:  Tatsunori Ikeda; Hisayoshi Murai; Shuichi Kaneko; Soichiro Usui; Daisuke Kobayashi; Manabu Nakano; Keiko Ikeda; Shin-Ichiro Takashima; Takeshi Kato; Masaki Okajima; Hiroshi Furusho; Masayuki Takamura
Journal:  J Physiol       Date:  2011-12-05       Impact factor: 5.182

Review 4.  Atrial fibrillation (chronic).

Authors:  Deirdre A Lane; Stavros Apostolakis; Christopher J Boos; Gregory Y H Lip
Journal:  BMJ Clin Evid       Date:  2011-11-10

5.  In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.

Authors:  Martin Aguilar-Shardonofsky; Edward J Vigmond; Stanley Nattel; Philippe Comtois
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

6.  Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program.

Authors:  J L M Hendriks; R Nieuwlaat; H J M Vrijhoef; R de Wit; H J G M Crijns; R G Tieleman
Journal:  Neth Heart J       Date:  2010-10       Impact factor: 2.380

Review 7.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Rate versus rhythm in atrial fibrillation: and how slow do you go?

Authors:  G Michael Allan; Christina Korownyk; Michael R Kolber
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

9.  Clinical pearls in cardiology.

Authors:  Stephen L Kopecky; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 10.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.